Immunovant

Update in progress

IMVT (NasdaqGS)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Immunovant is a clinical-stage immunology company developing monoclonal antibodies for autoimmune diseases. It is advancing IMVT-1402 for Graves’ disease, rheumatoid arthritis, myasthenia gravis, CIDP, cutaneous lupus erythematosus, and Sjögren’s syndrome; and batoclimab for myasthenia gravis, CIDP, and thyroid eye disease. Founded in 2018 and based in New York, Immunovant is a subsidiary of Roivant Sciences Ltd.

Company score

Sentiment: 0.20; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.22; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.00; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.07; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.13; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive